NCT02876107
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with metastatic sites that are not candidates for local therapy (i.e. radiation and/or surgery)
https://ClinicalTrials.gov/show/NCT02876107